Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gemini Therapeutics, Inc. - Common Stock (NQ: GMTX )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Dec 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 1.090 (20)
Ask (Size) 1.330 (1)
Prev. Close 1.350
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Why Minerva Surgical Shares Are Trading Higher By 166%; Here Are 26 Stocks Moving Premarket
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 166% to $0.4327 in pre-market trading after the company reported a $30 million private placement of common stock led by Accelmed Partners. 
Via Benzinga

Performance

More News

Read More
7 Short-Squeeze Stocks for Bold Contrarians to Consider
Via InvestorPlace
Gemini Therapeutics Announces Reverse Merger Pact With Hematology-Focused Company
Via Benzinga
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
From Kahn Swick & Foti, LLC
Via Business Wire
GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
From Gemini Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Via Benzinga
10 Biggest Price Target Changes For Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2022
Via Benzinga
What 5 Analyst Ratings Have To Say About Gemini Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
Via Benzinga
10 Biggest Price Target Changes For Thursday
Via Benzinga
Read Why Did Jefferies Downgrade Gemini Therapeutics To Hold
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Gemini Therapeutics Provides Corporate Update
From Gemini Therapeutics, Inc.
Via Business Wire
Gemini Therapeutics Provides GEM103 Program Update
From Gemini Therapeutics, Inc.
Via Business Wire
46 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points After Federal Reserve's Policy Update
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.